Ordering Recommendation

Aids in monitoring but is not recommended for diagnosis of carcinoid tumors. May be useful in monitoring nonsecretory sympathetic and parasympathetic neuroendocrine tumors.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube or plain red.

Specimen Preparation

Allow serum specimen to clot completely at room temperature. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.5 mL)

Storage/Transport Temperature

Frozen

Unacceptable Conditions

Plasma

Remarks
Stability

After separation from cells: Room Temperature: 48 hours; Refrigerated: 3 days; Frozen: 3 months

Methodology

Immunofluorescence

Performed

Sun-Sat

Reported

1-4 days

Reference Interval

0-187 ng/mL

Interpretive Data

This test is performed using the BRAHMS CGA II Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease and should be evaluated in combination with clinical symptoms, diagnostic evidence, and/or other laboratory parameters. The change ofCgA concentration over time provides diagnostic information whether a tumor progression has occurred.

An increase of CgA serum concentrations of more than 50% to avalue of greater than 100 ng/ml between consecutive monitoring visits defines a positive test result, representing a higher probability that a tumor progression has occurred.

A change of CgA serum concentrations of equal or less than 50% increase between monitoring visits or to a value of 100 ng/ml or less defines a negative test result, representing a lower probability that a tumor progression has occurred.  Nontumor related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, cancers other than neuroendocrine tumors, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least 14 days prior to testing.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

86316

Components

Component Test Code* Component Chart Name LOINC
3002868 Chromogranin in serum 9811-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • CgA
  • Chromogranin
Chromogranin A, Serum